CLINICAL STUDY

Prognostic significance of the preoperative serum levels of soluble form of endoglin in gastric cancer patients

Gomceli I1, Tez M2, Bostancı EB1, Kemik AS3, Demiriz B2, Akoglu M1

Turkiye Yuksek Ihtisas Education and Research Hospital, Department of Gastroenterologic Surgery, Turkey.
mesuttetz@yahoo.com

Abstract: Background: Gastric cancer is the second commonest cause of cancer-associated deaths in the world. Its molecular markers can be useful not only for the diagnostic pursuit but also for prognostic purposes. Endoglin was proposed as a marker of neovascularization in solid malignancies. A circulating form of endoglin is referred to as soluble endoglin (sol-end). The purpose of this study was to investigate the clinical importance of serum level of soluble form of sol-end in gastric cancer patients.

Materials and methods: Serum levels of sol-end were measured in 69 healthy controls and in 60 gastric adenocarcinoma patients with ELISA and serum levels of sol-end were compared with clinicopathological features and outcomes in gastric cancer patients.

Results: Serum levels of sol-end in gastric adenocarcinoma patients were significantly higher than in control patients (p<0.001). The serum levels of sol-end did not differ relative to clinical and pathologic criteria.

Conclusion: Presented data suggest that serum levels of sol-end do not seem to be a valuable tool in the assessment of gastric cancer prognosis (Tab. 1, Ref. 11). Full Text in PDF www.elis.sk.

Key words: endoglin, gastric cancer, prognosis.

Cancer is still a major public health problem worldwide. According to the International Gastric Cancer Society, more than 800,000 people are affected by gastric cancer every year, and up to 650,000 people have succumbed to gastric cancer. It is likely that in 2020 gastric cancer will increase by 10% in the developing countries (1–3).

One of the recently described substances important for angiogenesis is endoglin. Endoglin, also known as CD105, is a receptor for transforming growth factor-β1 molecule, which binds preferentially to the activated endothelial cells participating in tumor angiogenesis, i.e. with weak or negative expression in vascular endothelium of normal tissues. Endoglin is induced by hypoxia. Endoglin assessed in gastric cancer tissues using immunohistochemistry was shown to correlate with newly formed blood vessels. Therefore it is very useful for assessment of neo-angiogenesis of malignant neoplasms (4, 5). Endoglin is expressed not only on cell surface, since its soluble form can be detected also in blood (4, 6). But, there are no sufficient data on the prognostic significance of serum level of soluble form of endoglin (sol-end) levels in gastric cancer patients.

In the present study, we assessed a possible role for preoperative serum level of sol-end as a poten predictor of prognosis in gastric cancer patients.

Material and method

Sixty consecutive patients with gastric adenocarcinoma were enrolled in this study. The diagnoses in all patients were confirmed by histopathologic examination of their gastric resection specimens. Informed written consent was obtained before patient enrollment. This study has been approved by the institutional review board of Turkiye Yuksek Ihtisas Education and Research Hospital. Patients under the age of 18, those with history of malignant disease, patients with synchronous tumor, patients with gastric tumor except adenocarcinoma, and patients who had received chemotherapy or radiation therapy before current surgical therapy were excluded from the study.

Surgery consisted of subtotal or total gastrectomy and D2 (i.e., extended) lymph-node dissection in all patients, except in cases with peritoneal or distant metastasis. Serial sections from paraffin-embedded tissue blocks were obtained from gastric tumor tissues and used for histological diagnosis. Microdissected areas were assessed by an expert pathologist to estimate the status of perineural and vascular invasion, depth of tumor invasion, lymph-node metastasis and histological grading. The American Joint Committee on Cancer (AJCC), TNM Staging Classification of the Stomach (7th ed., 2010) was used for staging the tumor.

Control blood samples were obtained from 60 individuals who visited health examination clinics with minimal gastritis or normal appearance of the gastric mucosa on endoscopic examination. Blood samples were collected before malignancies were treated surgically. Samples were allowed to clot, and serum was obtained after sample centrifugation. Serum samples were stored frozen at -20 °C. Repeated thawing and freezing of samples was
avoided. Soluble form of endoglin in serum was assessed by sandwich ELISA using diagnostic kit manufactured by R&D Systems (USA). The standard range of this kit is from 0.15 to 10 ng/ml and the minimum detectable dose is 0.007 ng/ml.

Statistical analysis

SPSS for Windows 11.5 (Chi. Il., USA) was used for statistical analysis. Descriptive statistics were presented as mean ± standard deviation. The demographic characteristics of patients and controls were compared using the χ² square test and Student’s t test. Shapiro–Wilk test was used for assessing normality. Gaussian distribution of data for serum levels of sol-end in study subjects and differences in serum levels of sol-end were compared using Student’s t test and one-way ANOVA test when appropriate. Correlations were evaluated using the Pearson correlation test. The survival probabilities were calculated using the Kaplan–Meier method. Differences between two groups were determined using the log-rank test. The influence of each significant predictor identified by log rank test was assessed by multivariate analysis using Cox’s proportional hazards model. Significance was presumed at p<0.05.

Results

There were 38 (55.07 %) male and 31 (44.93 %) female individuals in the control group with mean age of 55 (43–68). Serum endoglin levels were detectable in all healthy controls. The mean serum level of sol-end in healthy controls was 13.72±3.44 ng/mL. There was no significant difference in serum level of sol-end between the male and female controls (Males: 13.67±17 ng/mL and females: 13.86±3.10 ng/mL respectively, p=0.493). No correlation was found between serum levels of sol-end and age (r=0.084; p=0.497).

After serum investigation of the patients with gastric adenocancer, endoglin was detectable in all individuals. Serum levels of sol-end in gastric adenocancer patients were significantly higher than those in healthy controls (62.76±17.06 ng/mL versus 13.72±3.44 ng/mL, respectively; p<0.001).

The relationship between serum levels of sol-end and clinicopathologic variables of gastric cancer were evaluated (Tab. 1). The serum levels of sol-end did not differ significantly with histopathologic grade, tumor size, tumor-node-metastasis (TNM) stage, tumor localization, lymph node metastases, positive lymph node ratio, perivasular invasion, perineural invasion, age and sex.

Univariate analysis showed the TNM stage (p=0.006), and ratio of metastatic lymph nodes to retrieved lymph nodes (p=0.002) invasion to be significant factors affecting the overall survival. Multivariate regression analysis showed the TNM stage (hazard ratio, 6.65; 95% CI, 2.14–20.41; p=0.003), to be a single significant independent factor for overall survival.

Discussion

Endoglin, a receptor for transforming growth factor β1 and β3 is expressed predominantly on newly formed microvessels.
clinical outcome (9). Endoglin was also found to be expressed by
tumor cells in Ewing sarcoma and melanoma. Endoglin expression
in these two types of cancer correlated with tumor cell plasticity
and participates in the formation of vascular-like structures (10).
On the other hand; the strong expression of endoglin indicated a
poor prognosis in gastric cancer (5). The correlation of VEGF/
endoglin expression with the clinicopathological parameters
of gastric cancer showed that the high expression of VEGF/endoglin
was correlated only with lymph node metastasis (5). In mentioned
study, the 10-year survival rate was 27.77 % for patients with
high VEGF/ endoglin-expressing tumors, which was significantly
lower than the rate among patients with lower VEGF/ endoglin
expressing tumors. Endoglin expression emerged as not independent
variables of adverse prognostic significance. As seen, the
prognostic significance of endoglin expression varies depending
on the type of cancer.

The extracellular domain of membrane-bound endoglin can
be proteolytically cleaved, releasing a circulating form of endog-
lin named soluble endoglin. Increased levels of sol-end are linked
to the pathogenesis of severe vascular diseases such as systemic
sclerosis and pre-eclampsia (4).

Soluble endoglin has been reported to rise in breast cancer
patients who developed metastases, as compared to both normal
controls and cancer patients without distant spread (11). Plasma
sol-end level in prostate cancer has a predictive value for metas-
tasis to the pelvic lymph nodes (7). High levels of sol- end are
also present in myeloid malignancies that are characterized by a
high cellular proliferation rate (7). Nonetheless, other reports on
esophageal and ovarian tumors failed to find sol-end levels as a
valuable marker in the assessment of cancer spread (4).

Mysliwiec et al and his colleagues investigated the serum and
plasma endoglin levels in patients with gastric cancer. Twenty-six
patients with gastric cancer were included in mentioned study. The
authors did not find a difference between plasma and serum levels
of endoglin. Also, authors did not find any significant correlations
between endoglin in plasma or in serum and any clinical or patho-
logical parameters (4). We achieved similar results in our study. In
our study, serum levels of sol-end in patients with gastric cancer
were higher than those in controls. However; high levels of sol-
end had no relationship with clinical pathological variables and
prognosis. The difference between the prognostic importance of
serum levels of sol-end and tissue endoglin expression is a matter
to be investigated. In conclusion, there is no prognostic significance
of serum levels of sol-end in gastric cancer patients.

References

4. Mysliwiec P, Pawlak K, Bandurski R, Kedra B. Soluble angiogen-
esis markers in gastric tumor patients. Folia Histochem Cytobiol 2009;
47: 81–86.
5. Nikiteas NI, Tzanakis N, Theodoropoulos G, Atsaves V, Christoni
Z, Karakitsos P et al. Vascular endothelial growth factor and endoglin
Tsai H et al. Association of serum endoglin with metastasis in patients
with colorectal, breast, and other solid tumors, and suppressive effect of
7. Pérez-Gómez E, Del Castillo G, Juan Francisco S, López-Novoa JM,
Bernabéu C, Quintanilla M. The role of the TGF-β coreceptor endoglin
Identification of an invasion and tumor-suppressing gene, Endoglin (ENG),
silenced by both epigenetic inactivation and allelic loss in esophageal squa-
al. Endoglin expression in breast tumor cells suppresses invasion and me-
tastasis and correlates with improved clinical outcome. Oncogene 2011;
30: 1046–1058.
10. Pardali E, van der Schaft DW, Wiercinska E, Gorter A, Hogen-
doorn PC, Grijffioen AW et al. Critical role of endoglin in tumor cell
Plasma levels of soluble CD105 correlate with metastasis in patients with

Received October 19, 2011.
Accepted July 20, 2013.